001     147217
005     20240303003951.0
024 7 _ |a 10.1002/jmri.26692
|2 doi
024 7 _ |a pmid:30793419
|2 pmid
024 7 _ |a 1053-1807
|2 ISSN
024 7 _ |a 1522-2586
|2 ISSN
024 7 _ |a altmetric:70354486
|2 altmetric
037 _ _ |a DKFZ-2019-02343
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Schwarz, Daniel
|0 P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6
|b 0
|e First author
245 _ _ |a Susceptibility-weighted imaging in malignant melanoma brain metastasis.
260 _ _ |a New York, NY
|c 2019
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1681388167_19516
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The value of cerebral susceptibility-weighted imaging (SWI) in malignant melanoma (MM) patients remains controversial and the effect of melanin on SWI is not well understood.To systematically analyze the spectrum of intracerebral findings in MM brain metastases (BM) on SWI and to determine the diagnostic value of SWI.Retrospective.In all, 100 patients with melanoma BM (69 having received radiotherapy [RT] and 31 RT-naïve) and a control group of 100 melanoma patients without BM were included. For detailed analysis of signal characteristics, 175 metastases were studied.Gradient echo SWI sequence at 1.5, 3.0, and 9.4 T.Signal characteristics from melanotic and amelanotic BMs on SWI with a focus on blooming artifacts were analyzed, as well as the presence and longitudinal dynamics of isolated SWI blooming artifacts in patients with and without BM.Chi-squared and Student's t-test were used for contingency table measures and group data of signal and clinical characteristics, respectively.Melanotic and amelanotic metastases did not show significant differences of SWI blooming artifacts (38% vs. 43%, P = 0.61). Most metastases without an initial SWI artifact developed a signal dropout during follow-up (80%; 65/81). Isolated SWI artifacts were detected more frequently in patients with BM (20 vs. 9, P = 0.03), of which the majority were found in patients who had received RT (17 vs. 3, P = 0.08). None of these isolated SWI blooming artifacts turned into overt metastases over time (median follow-up: 8.5 months). Similar findings persisted as remnants of successfully treated metastases (88%; 7/8).We conclude that SWI provides little additional diagnostic benefit over standard T1 -weighted imaging, as melanin content alone does not cause diagnostically relevant SWI blooming. Signal transition of SWI may rather indicate secondary phenomena like microbleeding and/or metal scavenging. Our results suggest that isolated SWI artifacts do not constitute vital tumor tissue but represent unspecific microbleedings, RT-related parenchymal changes or posttherapeutic remnants of former metastatic lesions.3 Technical Efficacy Stage: 5 J. Magn. Reson. Imaging 2019;50:1251-1259.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Niederle, Thomas
|b 1
700 1 _ |a Münch, Philipp
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 3
|u dkfz
700 1 _ |a Hassel, Jessica C
|b 4
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 5
|u dkfz
700 1 _ |a Platten, Michael
|0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
|b 6
|u dkfz
700 1 _ |a Winkler, Frank
|0 P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b
|b 7
|u dkfz
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 8
|u dkfz
700 1 _ |a Heiland, Sabine
|b 9
700 1 _ |a Delorme, Stefan
|0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
|b 10
|u dkfz
700 1 _ |a Bendszus, Martin
|b 11
700 1 _ |a Bäumer, Philipp
|0 P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a
|b 12
700 1 _ |a Breckwoldt, Michael
|0 P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303
|b 13
|e Last author
|u dkfz
773 _ _ |a 10.1002/jmri.26692
|g Vol. 50, no. 4, p. 1251 - 1259
|0 PERI:(DE-600)1497154-9
|n 4
|p 1251 - 1259
|t Journal of magnetic resonance imaging
|v 50
|y 2019
|x 1522-2586
909 C O |p VDB
|o oai:inrepo02.dkfz.de:147217
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)a46ef05266eafb5f42c207880f97ebf6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Tumor immunology
|x 0
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J MAGN RESON IMAGING : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)D170-20160331
|k D170
|l KKE Neuroimmunologie und Hirntumorimmunologie
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 2
920 1 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 3
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)D170-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)B320-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21